tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2012-2-110-115tumors-124Research ArticleОБЗОРЫ И АНАЛИТИКАREVIEWS AND ANALYSISРАЗРАБОТКА СПОСОБОВ ПОВЫШЕНИЯ ЭФФЕКТИВНОСТИ ХИМИОТЕРАПИИ НА ОСНОВЕ МАЛЫХ ИНТЕРФЕРИРУЮЩИХ РНКБавыкинА. С.КоротаеваА. А.СырцевА. В.КарпухинА. В.

ФБГУ «Медико-генетический научный центр» РАМН, Москва

ТюляндинС. А.ФБГУ «Медико-генетический научный центр» РАМН, МоскваRussian Federation20122205201522110115Copyright © Бавыкин А.С., Коротаева А.А., Сырцев А.В., Карпухин А.В., Тюляндин С.А., 20152015Бавыкин А.С., Коротаева А.А., Сырцев А.В., Карпухин А.В., Тюляндин С.А.Бавыкин А.С., Коротаева А.А., Сырцев А.В., Карпухин А.В., Тюляндин С.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/124

Появление в последние 10-15 лет химиопрепаратов нового поколения позволило значительно улучшить показатели выживаемости для онкологических больных. Однако злокачественные опухоли многих пациентов, получающих химиотерапию, оказываются нечувствительными к проводимому лечению. Другой проблемой большинства современных химиотерапевтических препаратов является высокая степень проявления побочных, токсических реакций для организма. Следует также отметить высокую стоимость и длительность лечения. В связи с этим как в нашей стране, так и за рубежом активно ведется поиск альтернативных лечебных подходов, способных, если не заменить, то хотя бы усилить чувствительность опухоли к проводимому стандартному лечению.

интерферирующие РНКтаргетная терапияReferencesArango D, Wilson AJ, Shi Q, Corner GA, Arañes MJ, Nicholas C, Lesser M, Mariadason JM, Augenlicht LH. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer. 2004 Nov 29;91(11):1931-46.Arango D, Wilson AJ, Shi Q, Corner GA, Arañes MJ, Nicholas C, Lesser M, Mariadason JM, Augenlicht LH. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer. 2004 Nov 29;91(11):1931-46.Baumeister P, Dong D, Fu Y, Lee AS. Transcriptional induction of GRP78/BiP by histone deacetylase inhibitors and resistance to histone deacetylase inhibitor-induced apoptosis. Mol Cancer Ther. 2009 May;8(5):1086-94.Baumeister P, Dong D, Fu Y, Lee AS. Transcriptional induction of GRP78/BiP by histone deacetylase inhibitors and resistance to histone deacetylase inhibitor-induced apoptosis. Mol Cancer Ther. 2009 May;8(5):1086-94.Chen SH, Shine HD. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. 1994, Proc Natl Acad Sci USA 91(8):3054–3057.Chen SH, Shine HD. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. 1994, Proc Natl Acad Sci USA 91(8):3054–3057.Chowdhury S, Chester KA, Bridgewater J, Collins MK, Martin F. Efficient retroviral vector targeting of carcinoembryonic antigen-positive tumors. Mol Ther. 2004 Jan;9(1):85-92.Chowdhury S, Chester KA, Bridgewater J, Collins MK, Martin F. Efficient retroviral vector targeting of carcinoembryonic antigen-positive tumors. Mol Ther. 2004 Jan;9(1):85-92.Di Paolo, D.; Brignole, C.; Pastorino, F.; Carosio, R.; Zorzoli, A.; Rossi, M.; Loi, M.; Pagnan, G.; Emionite, L.; Cilli, M.; Bruno, S.; Chiarle, R.; Allen, T. M.; Ponzoni, M.; Perri, P. Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK. Mol. 8. Ther. 2011, 19, 1131–40Di Paolo, D.; Brignole, C.; Pastorino, F.; Carosio, R.; Zorzoli, A.; Rossi, M.; Loi, M.; Pagnan, G.; Emionite, L.; Cilli, M.; Bruno, S.; Chiarle, R.; Allen, T. M.; Ponzoni, M.; Perri, P. Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK. Mol. 8. Ther. 2011, 19, 1131–40Jonathan K. Watts, Glen F. Deleavey and Masad J. Damha Chemically modified siRNA: tools and applications, Drug Discov Today. 2008 Oct;13 (19-20):842-55Jonathan K. Watts, Glen F. Deleavey and Masad J. Damha Chemically modified siRNA: tools and applications, Drug Discov Today. 2008 Oct;13 (19-20):842-55Harradine K.A., Kassner M., Chow D., Aziz M., Von Hoff D.D., Baker J.B., Yin H, and Pelham R.J. Functional Genomics Reveals Diverse Cellular Processes That Modulate Tumor Cell Response to Oxaliplatin. Mol Cancer Res 2011; 9:173-182.Harradine K.A., Kassner M., Chow D., Aziz M., Von Hoff D.D., Baker J.B., Yin H, and Pelham R.J. Functional Genomics Reveals Diverse Cellular Processes That Modulate Tumor Cell Response to Oxaliplatin. Mol Cancer Res 2011; 9:173-182.Hsu C.Y., Hsiao J.P., Shieh M.J., Lai P.S. siRNA and Paclitaxel Loaded PEG-PCL-PEI Tri-block Polymeric Micelle for Gene and Chemo-therapy Applications in Multidrugresistance cancer cell. Nanotech 2011 Vol. 3 p225-228Hsu C.Y., Hsiao J.P., Shieh M.J., Lai P.S. siRNA and Paclitaxel Loaded PEG-PCL-PEI Tri-block Polymeric Micelle for Gene and Chemo-therapy Applications in Multidrugresistance cancer cell. Nanotech 2011 Vol. 3 p225-228Germano I.M, Fable J., Gultekin S.H., Silvers A. Clinical Study Adenovirus/herpes simplex-thymidine kinase/ ganciclovir complex:preliminary results of a phase I trial in patients with recurrent malignant gliomas. Journal of Neuro-Oncology 65: 279–289, 2003.Germano I.M, Fable J., Gultekin S.H., Silvers A. Clinical Study Adenovirus/herpes simplex-thymidine kinase/ ganciclovir complex:preliminary results of a phase I trial in patients with recurrent malignant gliomas. Journal of Neuro-Oncology 65: 279–289, 2003.Gomes-da-Silva LC, Fonseca NA, Moura V, Pedroso de Lima MC, Simões S, Moreira JN. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Acc Chem Res. 2012 Jul 17;45(7):1163-71.Gomes-da-Silva LC, Fonseca NA, Moura V, Pedroso de Lima MC, Simões S, Moreira JN. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Acc Chem Res. 2012 Jul 17;45(7):1163-71.Goodman JC, Trask TW. Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: pathologic, radiologic, and molecularstudies. Hum Gene Ther 7(10): 1241–1250, 1996Goodman JC, Trask TW. Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: pathologic, radiologic, and molecularstudies. Hum Gene Ther 7(10): 1241–1250, 1996Günther M, Lipka J, Malek A, Gutsch D, Kreyling W, Aigner A. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm. 2011 Apr; 77(3):438-49.Günther M, Lipka J, Malek A, Gutsch D, Kreyling W, Aigner A. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm. 2011 Apr; 77(3):438-49.Liang H., Zhang J, Shao C, Zhao L., Xu W., Sutherland L.C., Wang K. Differential Expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues. Journal of Experimental & Clinical Cancer Research April 2012, 31:36,Liang H., Zhang J, Shao C, Zhao L., Xu W., Sutherland L.C., Wang K. Differential Expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues. Journal of Experimental & Clinical Cancer Research April 2012, 31:36,Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L and Johnston PG. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene (2006) 25, 838–848Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L and Johnston PG. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene (2006) 25, 838–848Pfeifer A, Kessler T, Silletti S, Cheresh DA, Verma IM: Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci USA 2000, 97:12227-12232.Pfeifer A, Kessler T, Silletti S, Cheresh DA, Verma IM: Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci USA 2000, 97:12227-12232.Samimi G, Manorek G, Castel R, Breaux JK, Cheng TC, Berry CC, Los G, Howell SB. cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemother Pharmacol. 2005 Jan; 55(1):1-11.Samimi G, Manorek G, Castel R, Breaux JK, Cheng TC, Berry CC, Los G, Howell SB. cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemother Pharmacol. 2005 Jan; 55(1):1-11.Santos, A. O.; da Silva, L. C.; Bimbo, L. M.; de Lima, M. C.; Simoes, S.; Moreira, J. N. Design of peptide-targeted liposomes containing nucleic acids. Biochim. Biophys. Acta 2010, 1798, 433–41Santos, A. O.; da Silva, L. C.; Bimbo, L. M.; de Lima, M. C.; Simoes, S.; Moreira, J. N. Design of peptide-targeted liposomes containing nucleic acids. Biochim. Biophys. Acta 2010, 1798, 433–41Su WP, Cheng FY, Shieh DB, Yeh CS, Su WC. PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells, International Journal of Nanomedicine, 2012 Volume 2012:7 Pages 4269 – 4283.Su WP, Cheng FY, Shieh DB, Yeh CS, Su WC. PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells, International Journal of Nanomedicine, 2012 Volume 2012:7 Pages 4269 – 4283.Szécsi J, Drury R, Josserand V, Grange MP, Boson B, Hartl I, Schneider R, Buchholz CJ, Coll JL, Russell SJ, Cosset FL, Verhoeyen E. Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HAprotease interactions. Mol Ther. 2006 Nov;14(5):735-44Szécsi J, Drury R, Josserand V, Grange MP, Boson B, Hartl I, Schneider R, Buchholz CJ, Coll JL, Russell SJ, Cosset FL, Verhoeyen E. Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HAprotease interactions. Mol Ther. 2006 Nov;14(5):735-44Tandle A, Blazer DG 3rd, Libutti SK. Antiangiogenic gene therapy of cancer: recent developments.J Transl Med. 2004 Jun 25;2(1):22.Tandle A, Blazer DG 3rd, Libutti SK. Antiangiogenic gene therapy of cancer: recent developments.J Transl Med. 2004 Jun 25;2(1):22.Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet. 2007 Aug; 8(8):573-87.Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet. 2007 Aug; 8(8):573-87.Wang J, Bown C, Young L. Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78. Mol Pharmacol 1999; 55: 521–7.Wang J, Bown C, Young L. Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78. Mol Pharmacol 1999; 55: 521–7.Zhu C, Jung S, Luo S, Meng F, Zhu X, Park TG, Zhong Z. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMAPCL-PDMAEMA triblock copolymers. Biomaterials, 2010 Mar; 31(8):2408-16.Zhu C, Jung S, Luo S, Meng F, Zhu X, Park TG, Zhong Z. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMAPCL-PDMAEMA triblock copolymers. Biomaterials, 2010 Mar; 31(8):2408-16.

The authors declare that there are no conflicts of interest present.